Global gynecology drugs market stood at USD14139.56 million in 2021 and is forecast to witness CAGR of over 8% in the upcoming five years. Increasing incidences of gynecological cancer and other gynecological diseases among women are the primary drivers for the growth of gynecology drugs market.
Global gynecology drugs market report is segmented based on therapeutics, indication, distribution channel, and region. Based on the indication, market is split into Contraception, Gynecology Infections, Female Infertility, Postmenopausal disorders, Polycystic Ovary Syndrome, Gynecology Cancers, and Endometriosis. Global gynecology drugs market is being dominated majorly by the contraception segment. The segment accounted for the share of 26.68% in 2021 and the segment is projected to grow at CAGR of 8.96% through 2027.
In terms of region, North America region is expected to lead the global gynecology drugs market during the forecast period. The regional growth can be attributed to the increasing incidences of gynecological diseases owing to changing lifestyle of the female population and rising awareness regarding health and well-being. Besides, the expanding older female population and high personal disposable income are some of the factors fueling the growth of the gynecology drugs market in the region.
Some of leading players operating in the market include Amgen Inc., F. Hoffmann La Roche Ltd., Novartis AG, Bayer AG, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, AstraZeneca Plc, Lupin Limited, Johnson and Johnson, Sanofi SA, Ferring Pharmaceuticals among others.
Download Sample Report